PRAX — Praxis Precision Medicines, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1689548 ·
Last close
$307.83
Market Cap
$8.58B
52W High
$366.52
52W Low
$238.77
ADV30
497,007
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -105,860,000 | -92,561,000 | 1,460,202,000 | 536,333,000 | 50,241,000 |
| Dec 2025 | 0 | — | -97,044,000 | -88,911,000 | 937,907,000 | 357,329,000 | 59,771,000 |
| Sep 2025 | 0 | — | -78,359,000 | -73,934,000 | 396,388,000 | 149,527,000 | 52,883,000 |
| Jun 2025 | 0 | — | -76,067,000 | -71,127,000 | 452,832,000 | 157,415,000 | 48,608,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-249,068,000
Investing CF
$-311,148,000
Financing CF
$702,173,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-13.46
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,140,008,000
Inventory
—
Receivables
—
ST Investments
$242,002,000
EBIT TTM
$-326,198,000
Pretax Income TTM
$-303,268,000
Interest Exp TTM
—
Analysts
17
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -326,198,000 | -303,268,000 | 937,907,000 | 59,771,000 | — | -249,068,000 |
| Dec 2024 | 8,553,000 | -200,165,000 | -182,819,000 | 483,110,000 | 37,660,000 | — | -131,757,000 |
| Dec 2023 | 2,447,000 | -126,373,000 | -123,277,000 | 87,948,000 | 18,279,000 | — | -111,136,000 |
| Dec 2022 | 0 | -214,986,000 | -214,029,000 | 115,128,000 | 39,022,000 | — | -185,043,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$770,000
NetIncome TTM
$-165,192,000
OpCashFlow TTM
$0
Assets (Latest)
$483,110,000
Forward EPS
$-9.66
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IONS | IONIS PHARMACEUTICALS INC | $8.60B | $51.77 | — |
| SYRE | Spyre Therapeutics, Inc. | $8.54B | $98.33 | — |
| PTGX | Protagonist Therapeutics, Inc | $8.79B | $136.64 | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.84B | $83.52 | — |
| ALKS | Alkermes plc. | $8.22B | $48.99 | — |
News headlines (Yahoo Finance, 1h cache)
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
2026-07-30 20:01 · Yahoo
Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs
2026-07-15 14:01 · Yahoo
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
2026-07-07 12:00 · Yahoo
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 20:01 · Yahoo
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
2026-06-29 20:30 · Yahoo
Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation
2026-06-22 12:47 · Yahoo
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of
2026-06-22 12:00 · Yahoo
Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack Up
2026-06-15 03:11 · Yahoo
BTIG Reaffirms Buy Rating for Praxis Precision Medicines (PRAX)
2026-06-11 10:20 · Yahoo
Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings
2026-06-05 15:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.